Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »
HomeLetteratura
Archivio

Objectives. This study aimed to investigate the effectiveness of pharmacist intervention in reducing and preventing prescribing errors of investigational drugs for cancer patients. Materials and methods. A retrospective study was conducted during two periods: a baseline period from December 2015 to June 2016 and an intervention period from July 2016 to

Effects of pharmacist interventions on reducing prescribing errors of investigational drugs in oncology clinical trials. J Oncol Pharm Pract 2020;26(1):29-35 https://doi.org/10.1177/1078155219834723 /  Moon JY, Lee Y, Han JM, Lee MH, Yee J, Song MK, Kim YJ, Gwak HS.

Gender disparity exists in leadership roles within healthcare. While the majority of the healthcare workforce is comprised of women, significantly fewer women occupy leadership positions, particularly at executive and board levels. As the field of oncology pharmacy continues to rapidly expand and evolve, an assessment of the current state of

Women in oncology pharmacy leadership: A white paper. J Oncol Pharm Pract 2020;26(1):175-186 doi: 10.1177/1078155219874872 /  Shillingburg A, Michaud LB, Schwartz R, Anderson J, Henry DW, endorsed by the Hematology/Oncology Pharmacy Association (HOPA).

Despite advances in the management of hematologic malignancies, a significant proportion of patients die of their disease. We used administrative databases in Ontario, Canada (between 2005 and 2013) to determine the number of days spent at home in the last 6 months of life. We studied the predictors of the median

Days spent at home in the last 6 months of life: a quality indicator of end of life care in patients with hematologic malignancies. Leukemia & Lymphoma 2020;61(1):146-155 DOI: 10.1080/10428194.2019.1654095 /  Cheung MC, Croxford R, Earle CC, Singh S.

Background: Discharge medication reconciliation (MedRec) is designed to reduce medication errors and inform patients and key postdischarge providers, but it has been difficult to implement routinely in Canadian hospitals. Objectives: To evaluate and optimize a new discharge MedRec quality audit tool and to use it at 3 urban teaching hospitals. Methods: The

Evaluation of a Novel Audit Tool for Medication Reconciliation at Hospital Discharge. Can J Hosp Pharm 2020;72(6) DOI: http://dx.doi.org/10.4212/cjhp.v72i6.2941 /  Holbrook A, Bannerman H, Ahmed A, Georgy M, Liu JT, Troyan S, Watt A.

Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 2020;105:297-316 doi:10.3324/haematol.2019.229781 /  Yakoub-Agha I, Chabannon C, Bader P, Basak GW, Bonig H, Ciceri F, Corbacioglu S, Duarte RF, Einsele H, Hudecek M, Kersten MJ, Köhl U, Kuball J, Mielke S, Mohty M, Murray J, Nagler A, Robinson S, Saccardi R, Sanchez-Guijo F, Snowden JA, Srour M, Styczynski J, Urbano-Ispizua A, Hayden PJ, Kröger N.

Purpose of review. Registries provide ‘real world’ perspectives on the natural history and outcomes for many clinical conditions. The purpose of this review is to identify registries for nonmalignant hematological disease and to describe the operation of a successful long-term registry for patients with severe chronic neutropenia. Recent findings. There was

Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry. Current Opinion in Hematology 2020;27(1):18-26. /  Dale DC, Bolyard AA, Steele LA, Zeidler C, Welte K for the Severe Chronic Neutropenia International Registry.

Background. A limited evidence base and lack of clear clinical guidelines challenge healthcare systems’ adoption of precision medicine. The effect of these conditions on demand is not understood. Objective. This research estimated the public’s preferences and demand for precision medicine outcomes. Methods. A discrete-choice experiment survey was conducted with an online sample

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study. PharmacoEconomics 2020;38(1):57–68. /  Regier DA, Veenstra DL, Basu A, Carlson JJ.

Objectives: Clinical pharmacist support for patients with type 2 diabetes mellitus (T2DM) can optimize patient outcomes and medication adherence. However, there is limited understanding of what pharmacists’ roles patients perceive to be most helpful in T2DM management interventions. This study describes experiences of minority patients with uncontrolled T2DM

Clinical pharmacists in diabetes management: What do minority patients with uncontrolled diabetes have to say? Journal of the American Pharmacists Association 2020;S1544-3191(20)30037. DOI https://doi.org/10.1016/j.japh.2020.01.024 /  Nabulsi NA, Yan CH, Tilton JJ, Gerber BS, Sharp LK

Gaucher disease (GD) is a recessively inherited lysosomal storage disorder in which sphingolipids accumulates in the macrophages that transform into Gaucher cells. A growing body of evidence indicates that red blood cells (RBC) represent important actors in GD pathophysiology. We previously demonstrated that altered RBC properties including increased Lyso‐GL1 levels,

Semaphorin 7A: a novel marker of disease activity in Gaucher disease. Am J Hematol 2020; doi:10.1002/ajh.25744 /  Franco M, Reihani N, Dupuis L, Collec E, de Villemeur TB, de Person M, Moussa F, Berger MG, Belmatoug N, Le Van Kim C.

In this issue of Blood, Pan et al highlight their approach toward dual-antigen chimeric antigen receptor (CAR) T-cell targeting in an effort to reduce the risk of immune escape in pediatric B-cell acute lymphoblastic leukemia (B-ALL). They demonstrate the feasibility of sequentially administering CD19 CAR T cells followed by CD22

The one-two punch (of CAR T cells). Blood 2020;135(5):303–304 https://doi.org/10.1182/blood.2019004272 /  Shah NN.